MISSION PHARMACAL ACQUIRES TINDAMAX

Mission Pharmacal today announcedthat it has acquired the U.S. manufacturing and commercial rights for Tindamax (tinidazole tablets) from Presutti Laboratories, LLC. Tindamax is a prescription drug therapy for trichomoniasis, the most common non-viral sexually transmitted disease (STD), which is estimated to occur at a rate of about 7.4 million cases in the United States annually. The second-generation 5-nitroimidazole compound is also indicated for the treatment of intestinal infections giardiasis and intestinal amebiasis, as well as amebic liver abscess. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-20-2006/0004343883&EDATE=)